| Date Filed | Type | Description |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/31/2023 |
4
| SCHUMACHER RICHARD T (President, CEO) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 1,264 shares
@ $0.87, valued at
$1.1k
|
|
| 05/31/2023 |
4
| PETERSON JEFFREY N (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 3,292 shares
@ $0.87, valued at
$2.9k
|
|
| 05/31/2023 |
4
| Urdea Michael S (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 796 shares
@ $0.87, valued at
$692.5 |
|
| 05/31/2023 |
4
| Lazarev Alexander V (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 1,041 shares
@ $0.87, valued at
$905.7 |
|
| 05/31/2023 |
4
| Pollack Kevin (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 808 shares
@ $0.87, valued at
$703 |
|
| 05/31/2023 |
4
| Mangiardi Vito J (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 174 shares
@ $0.87, valued at
$151.4 |
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ...|
Docs:
|
"CERTIFICATE OF DESIGNATION OF SERIES BB CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC. 1. Series BB Preferred Stock Designation and Rank . Designation. The designation of such series of the Preferred Stock shall be the Series BB Convertible Preferred Stock, par value $0.01 per share . The maximum number of shares of Series BB Preferred Stock shall be One Thousand shares. Rank. The Series BB Preferred Stock shall rank prior to the common stock, par value $0.01 per share of Pressure BioSciences, Inc. , and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series BB Preferred Stock . The Series BB Preferred Stock shall be subordinate t...",
"CERTIFICATE OF DESIGNATION OF SERIES CC CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC. 1. Series CC Preferred Stock Designation and Rank . Designation. The designation of such series of the Preferred Stock shall be the Series CC Convertible Preferred Stock, par value $0.01 per share . The maximum number of shares of Series CC Preferred Stock shall be Two Thousand shares. Rank. The Series CC Preferred Stock shall rank prior to the common stock, par value $0.01 per share , shall rank pari passu to the Series AA Preferred Stock, and shall rank prior to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred Stock . The Series CC Preferred Stock shall be subordinate to and rank junior to ..." |
|
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Interactive Data |
| 01/20/2023 |
4
| SCHUMACHER RICHARD T (President, CEO) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted 427,532 options to buy
@ $1.5, valued at
$641.3k
|
|
| 01/20/2023 |
4
| Ting Edmund Y (Senior VP of Engineering) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted 127,860 options to buy
@ $1.5, valued at
$191.8k
|
|
| 01/20/2023 |
4
| Lazarev Alexander V (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted options to buy
@ $1.5, valued at
$0 |
|
| 01/20/2023 |
4
| Pollack Kevin (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted 218,960 options to buy
@ $1.5, valued at
$328.4k
|
|
| 01/20/2023 |
4
| Urdea Michael S (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted 187,680 options to buy
@ $1.5, valued at
$281.5k
|
|
| 01/20/2023 |
4
| PETERSON JEFFREY N (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted 414,460 options to buy
@ $1.5, valued at
$621.7k
|
|
| 01/20/2023 |
4
| Mangiardi Vito J (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Granted 203,320 options to buy
@ $1.5, valued at
$305k
|
|
| 01/05/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| SCHUMACHER RICHARD T (President, CEO) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 1,206 shares
@ $1.24, valued at
$1.5k
|
|
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Pollack Kevin (Director) has filed a Form 4 on PRESSURE BIOSCIENCES INC|
Txns:
| Acquired 771 shares
@ $1.24, valued at
$956 |
|
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/06/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/21/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|